AACR 2023 | ctDNA linked to RFS in patients with HCC treated with neoadjuvant cemiplimab

Thomas Urban Marron, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the potential role of neoadjuvant cemiplimab in patients with hepatocellular carcinoma (HCC). Whilst adjuvant atezolizumab and bevacizumab have shown promising results, immunotherapy in the neoadjuvant setting may be more efficacious. An early decrease in circulating tumor DNA (ctDNA) was correlated with long term remission and relapse free survival (RFS). This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.